DOCKET NO.: LEA 31923 C2 / BAYE-0050 Application No.: 10/613,819 Office Action Dated: February 10, 2009

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

- 1.-10. (Canceled)
- 11. (Previously Presented) A method for treating an animal having both an endoparasitic infection and an ectoparasitic infection comprising administering to said animal a composition comprising: a therapeutically-effective amount of a first active ingredient selected from the group consisting of avermectin, 22,23-dihydroavermectin B₁, and milbemycin; and, a therapeutically-effective amount of a second active ingredient selected from the group consisting of agonists and antagonists of the nicotinergic acetylcholine receptors of insects.
- 12. (Previously Presented) The method according to claim 11 wherein said first active ingredient comprises an avermeetin, a milbemyein, or both, and said second active ingredient comprises a chloronicotinyl, a chlorothiazolyl, or both.
- 13. (Previously Presented) The method according to claim 11 wherein said first active ingredient comprises moxidectin.
- 14. (Previously Presented) The method according to claim 13 wherein said second active ingredient comprises imidacloprid.
- 15. (Previously Presented) The method according to claim 11 wherein said first active ingredient comprises ivermectin.
- 16. (Previously Presented) The method according to claim 15 wherein said second active ingredient comprises imidacloprid.
- 17. (New) A method for treating an animal having both an endoparasitic infection and an ectoparasitic infection comprising:

identifying an animal having both an endoparasitic infection and an ectoparasitic infection; and,

administering to said identified animal a composition comprising

DOCKET NO.: LEA 31923 C2 / BAYE-0050 Application No.: 10/613,819 Office Action Dated: February 10, 2009

- a therapeutically-effective amount of a first active ingredient selected from the group consisting of avermectin, 22,23-dihydroavermectin B_1 , and milbemycin; and.
- a therapeutically-effective amount of a second active ingredient selected from the group consisting of agonists and antagonists of the nicotinergic acetylcholine receptors of insects.
- 18. (New) The method according to claim 17 wherein said first active ingredient comprises an avermectin, a milbemycin, or both, and said second active ingredient comprises a chloronicotinyl, a chlorothiazolyl, or both.
- (New) The method according to claim 17 wherein said first active ingredient comprises moxidectin.
- (New) The method according to claim 19 wherein said second active ingredient comprises imidacloprid.
- 21. (New) The method according to claim 17 wherein said first active ingredient comprises ivermectin.
- 22. (New) The method according to claim 21 wherein said second active ingredient comprises imidacloprid.